Global Clinical Oncology NGS Market Size, Share, Growth, Trends, and Forecast (2024 - 2031)
Global Clinical Oncology NGS Market Scope: Historical Data (2021 – 2022), Base Year (2023), Forecast Period (2024 – 2031)
Market Segmentation: By Technology (Whole Genome Sequencing, Whole Exome Sequencing, and Targeted Sequencing & Resequencing Centrifuges), Workflow (Pre-Sequencing, Sequencing, and Data Analysis), Application (Screening (Sporadic Cancer, and Inherited Cancer), Companion Diagnostics, and Other Diagnostics), End-use (Hospitals, Clinics, and Laboratories), and Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)
Market Overview
The Global Clinical Oncology NGS Market was valued at USD 432.5 million in 2023 and is expected to reach USD 1,388.8 million by 2031 while growing at a CAGR of 15.7% during the forecast period (2024-2031).
*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report
Market Dynamics
This section of the report will analyze various driving and restraining factors that are expected to have a significant impact on the global clinical oncology NGS market growth. Clinical oncology Next-Generation Sequencing (NGS) involves applying NGS technologies to analyze cancer-related genetic information. Also known as high-throughput sequencing, NGS is an advanced method for rapidly and comprehensively sequencing the genetic material of individuals, including cancer patients.
Advancements in NGS technologies and the increasing incidence of cancer are expected to drive significant growth in the Clinical Oncology NGS market. Despite this potential, obstacles such as data management challenges and integration with traditional diagnostic methods may hinder market expansion.
Furthermore, the global clinical oncology NGS industry will be analyzed through various tools including PESTLE analysis, and Porter’s analysis.
Segmentation – By Technology Analysis
The Global Clinical Oncology NGS Market is segmented among Whole Genome Sequencing, Whole Exome Sequencing, and Targeted Sequencing & Resequencing Centrifuges, based on Technology. In 2023, Targeted Sequencing & Resequencing Centrifuges accounted for the majority of the market share*.
*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report
Segmentation – By Workflow Analysis
The Global Clinical Oncology NGS Market is segmented among Pre-Sequencing, Sequencing, and Data Analysis, based on Workflow. In 2023, Sequencing accounted for the majority of the market share*.
*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report
Global Clinical Oncology NGS Market: Regional Analysis
Based on region, the market is divided into six regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, North America dominated the market with the highest market share, while Asia Pacific is expected to grow with the highest CAGR during the forecast period (2024 – 2031).
*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report
Competitive Landscape
Some of the key players operating in the market are Illumina, Inc., Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd., Agilent Technologies, Myriad Genetics, Beijing Genomics Institute (BGI), Perkin Elmer, Foundation Medicine, Pacific Bioscience, and Exact Science.
Table of Contents:
1. Research Methodology and Market Scope
Research Methodology
Market Scope
2. Executive Summary
3. Global Clinical Oncology NGS Market Dynamics
Drivers
Restraints
Opportunity
4. Global Clinical Oncology NGS Industry Analysis
PEST Analysis
Porter's Five Force Analysis
Recent Deals Analysis
5. Global Clinical Oncology NGS Market Segmentation, By Technology
Global Clinical Oncology NGS Market Share Analysis, By Technology
Global Clinical Oncology NGS Market Growth Analysis, By Technology
Global Clinical Oncology NGS Market Trends, By Technology
o Whole Genome Sequencing
o Whole Exome Sequencing
o Targeted Sequencing & Resequencing Centrifuges
6. Global Clinical Oncology NGS Market Segmentation, By Workflow
Global Clinical Oncology NGS Market Share Analysis, By Workflow
Global Clinical Oncology NGS Market Growth Analysis, By Workflow
Global Clinical Oncology NGS Market Trends, By Workflow
o Pre-Sequencing
o Sequencing
o Data Analysis
7. Global Clinical Oncology NGS Market Segmentation, By Application
Global Clinical Oncology NGS Market Share Analysis, By Application
Global Clinical Oncology NGS Market Growth Analysis, By Application
Global Clinical Oncology NGS Market Trends, By Application
o Screening
Ø Sporadic Cancer
Ø Inherited Cancer
o Companion Diagnostics
o Other Diagnostics
8. Global Clinical Oncology NGS Market Segmentation, By End-use
Global Clinical Oncology NGS Market Share Analysis, By End-use
Global Clinical Oncology NGS Market Growth Analysis, By End-use
Global Clinical Oncology NGS Market Trends, By End-use
o Hospitals
o Clinics
o Laboratories
9. Global Clinical Oncology NGS Market Segmentation, By Region
Global Clinical Oncology NGS Market Share Analysis, By Region
Global Clinical Oncology NGS Market Growth Analysis, By Region
Global Clinical Oncology NGS Market Trends, By Region
o North America
o Europe
o Asia Pacific
o Latin America
o Middle East
o Africa
10. Competitive Landscape
Illumina, Inc.*
o Company Overview
o Financial Performance
o Key Development/Strategies
o SWOT Analysis
Thermo Fisher Scientific
F. Hoffmann-La Roche Ltd.
Agilent Technologies
Myriad Genetics
Beijing Genomics Institute (BGI)
Perkin Elmer
Foundation Medicine
Pacific Bioscience
Exact Science
*Similar analysis will be provided for each company listed above.
